“We are very pleased with the progress made to date in the Phase 1 clinical study with DCC-3014, our selective, and potent small molecule inhibitor of CSF1R,” said Michael D. Taylor, Ph.D., President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback